Vanguard Portfolio Management’s Parabilis Medicines Inc PBLS Stock Holding History

Vanguard Portfolio Management’s Portfolio PBLS Stock Details PBLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.6M	Buy	+1,302,479	New	+$36M	﹤0.01%	1808

Other funds holding PBLS

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Portfolio Management's PBLS Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 1,302,479 shares worth $35.6M. The stake represents ﹤0.01% of the portfolio and ranks #1808 among its holdings.

37 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

Vanguard Portfolio Management held 1,302,479 shares of Parabilis Medicines Inc worth $35.6M as of Q2 2026.
Parabilis Medicines Inc was a new Vanguard Portfolio Management position in Q2 2026.
Parabilis Medicines Inc made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1808 holding.
37 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.